Horiguchi J - Search Results

1

Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.

Kurozumi S, Yamaguchi Y, Matsumoto H, Inoue K, Kurosumi M, Oyama T, Horiguchi J, Fujii T, Shirabe K. Kurozumi S, et al. Among authors: horiguchi j. Med Mol Morphol. 2019 Jun;52(2):90-98. doi: 10.1007/s00795-018-0206-y. Epub 2018 Sep 27. Med Mol Morphol. 2019. PMID: 30259117

2

Immunohistochemical double staining with estrogen receptor and HER2 on primary breast cancer.

Horiguchi J, Koibuchi Y, Iijima K, Yoshida T, Yoshida M, Takata D, Oyama T, Iino Y, Morishita Y. Horiguchi J, et al. Int J Mol Med. 2003 Dec;12(6):855-9. Int J Mol Med. 2003. PMID: 14612957

3

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.

Kurozumi S, Inoue K, Takei H, Matsumoto H, Kurosumi M, Horiguchi J, Takeyoshi I, Oyama T. Kurozumi S, et al. Among authors: horiguchi j. BMC Cancer. 2015 Sep 7;15:622. doi: 10.1186/s12885-015-1641-y. BMC Cancer. 2015. PMID: 26345461 Free PMC article.

4

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.

Kurozumi S, Padilla M, Kurosumi M, Matsumoto H, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Ranger-Moore J, Allred DC, Dennis E, Nitta H. Kurozumi S, et al. Among authors: horiguchi j. Breast Cancer Res Treat. 2016 Jul;158(1):99-111. doi: 10.1007/s10549-016-3856-2. Epub 2016 Jun 18. Breast Cancer Res Treat. 2016. PMID: 27318853 Free PMC article.

5

Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer.

Kurozumi S, Yamaguchi Y, Hayashi S, Hiyoshi H, Suda T, Gohno T, Matsumoto H, Takei H, Horiguchi J, Takeyoshi I, Oyama T, Kurosumi M. Kurozumi S, et al. Among authors: horiguchi j. Cancer Med. 2016 Aug;5(8):1873-82. doi: 10.1002/cam4.780. Epub 2016 Jun 23. Cancer Med. 2016. PMID: 27334118 Free PMC article.

6

Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J. Kurozumi S, et al. Among authors: horiguchi j. J Hum Genet. 2017 Jan;62(1):15-24. doi: 10.1038/jhg.2016.89. Epub 2016 Jul 21. J Hum Genet. 2017. PMID: 27439682 Review.

7

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.

Kurozumi S, Matsumoto H, Hayashi Y, Tozuka K, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Kurosumi M. Kurozumi S, et al. Among authors: horiguchi j. BMC Cancer. 2017 May 22;17(1):354. doi: 10.1186/s12885-017-3331-4. BMC Cancer. 2017. PMID: 28532429 Free PMC article.

8

Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.

Kurozumi S, Fujii T, Matsumoto H, Inoue K, Kurosumi M, Horiguchi J, Kuwano H. Kurozumi S, et al. Among authors: horiguchi j. Med Mol Morphol. 2017 Dec;50(4):185-194. doi: 10.1007/s00795-017-0170-y. Epub 2017 Sep 21. Med Mol Morphol. 2017. PMID: 28936553 Review.

9

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.

Kurozumi S, Matsumoto H, Inoue K, Tozuka K, Hayashi Y, Kurosumi M, Oyama T, Fujii T, Horiguchi J, Kuwano H. Kurozumi S, et al. Among authors: horiguchi j. PLoS One. 2018 Aug 6;13(8):e0201846. doi: 10.1371/journal.pone.0201846. eCollection 2018. PLoS One. 2018. PMID: 30080878 Free PMC article.

10

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.

Kurozumi S, Inoue K, Matsumoto H, Fujii T, Horiguchi J, Oyama T, Kurosumi M, Shirabe K. Kurozumi S, et al. Among authors: horiguchi j. Sci Rep. 2019 Feb 7;9(1):1583. doi: 10.1038/s41598-018-38272-1. Sci Rep. 2019. PMID: 30733496 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

427 results

Search Page

Filters